The present invention relates to the treatment of neurological disorders and, in particular, to the diagnosis and treatment of neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS).
ALS is a progressive neurological disorder characterized by muscle fiber atrophy resulting from the degeneration of motor neurons in the spinal column and brain. ALS affects approximately 30,000 U.S. citizens, with only ≈10% of cases being classified as the familial form of ALS. In a subset of familial patients with mutations in the metabolic enzyme superoxide dismutase 1 (SOD1), the pathological progression may be attributed to an unknown gain of function associated with a mutant form of the enzyme, i.e., is SOD1 dependent. However in the majority of ALS cases the SOD1 gene contains no mutations, the activity of the SOD1 enzyme is normal, and the mechanism of disease pathology is unknown, i.e., not SOD1 dependent. Therefore, the remaining 90% of ALS cases are classified as sporadic cases, with no well-characterized genetic component or causal agent.
Although ALS is characterized by loss of motor neurons in the spinal cord resulting in muscle atrophy, the disease also manifests itself with changes in axon transport, protein aggregation, excitotoxicity, astrocytosis, mitochondrial dysfunction, microglial activation and synaptic remodeling. Microglial activation, astrocytosis and the presence of infiltrating inflammatory cells from outside the central nervous system have been well described. There is accumulation of IgG immunoreactive deposits in the spinal cord of ALS patients, infiltration of lymphocytes, dendritic cells, monocytes, and macrophages into the spinal cord in ALS.
Although at present ALS is inevitably progressive, there is considerable variation in the rate of progression and the length of life expectancy. Currently, more than half of those diagnosed with ALS will survive three or more years, 20 percent live at least 5 years and as many as ten percent live for 10 years or more.
Determining the stage of ALS in an individual patient can be difficult and, to some extent, subjective. One predominant measure of ALS progression relies upon self-assessment using the ALS Functional Rating Scale (ALSFRS) questionnaire, in which higher numbers represent better physiological condition. The ALSFRS form consists of 12 questions each scored from 0 to 4, addressing the ability of the patient to perform certain actions, such as upper limb function, lower limb function, swallowing and speaking functions, the use of feeding tubes, and the need for respiration assistance.
There exists a need for methods and systems that can evaluate ALS in patients in a more quantitative manner than a self-assessment questionnaire.
Methods and systems are disclosed for evaluating a neurological condition by employing at least one, and preferably multiple, motion sensors, each configured to be attached to a different body appendage, a memory associated with the sensors to periodically record movement data during periods of prescribed exercises; and a processor for analyzing changes in movement data over time to evaluate the progression of the neurological condition. In one embodiment, the neurological condition is ALS and at least four motion sensors are employed such that each arm and leg of the patient has an associated sensor. The sensors can be accelerometers that measure the displacement, velocity and acceleration of an associated limb during periods of prescribed exercise. For example, changes in the patient's ability to repeat a series of limb-lifting exercises or the measurement of limb tremors associated with the conduct of the exercises can be correlated with a baseline and/or normalized values and analyzed to classify the stage of ALS in a patient and/or predict the rate of progression.
In one aspect of the invention, systems for evaluating the progression of ALS are disclosed that can include at least a first accelerometer attachable to a first body limb of a patient and configured to measure first movement data, including acceleration of the first limb during a period of prescribed exercise, and a processor for analyzing the movement data over time to evaluate the progression of ALS in the patient.
The systems can further include a second accelerometer attachable to a second body limb of the patient and configured to measure second movement data, including the acceleration of the second limb during the period of prescribed exercise. Moreover, the system can include a third accelerometer attachable to a third body limb and configured to measure third movement data, including the acceleration of the third limb during the period of prescribed exercise. The system can further include a fourth accelerometer attachable to a fourth body limb performing these tasks. The body limbs are selected from the group consisting of a left arm, a right arm, a left leg and a right leg. For example, an arm (left or right) consists of any region between a shoulder and a hand. This includes an arm, a forearm, and a wrist. A leg consists of any region between a hip and a foot. This includes an upper leg, a lower leg and an ankle. In one preferred embodiment, four accelerometers are deployed on each of the wrists and ankles of the patient to obtain data from all four limbs.
In certain embodiments the system's processor analyzes the movement data by comparing one or more acceleration vector magnitudes (VM) over time, the acceleration vector magnitudes being defined by an equation:
VM=√{square root over (x2+y2+z2)}
wherein x, y, and z represent the magnitudes of limb acceleration as measured in the x, y and z directions.
The accelerometer can be integrated into a sensor unit that includes a power supply, e.g., batteries, and a transmitter able to communicate wirelessly, e.g., by FM, RF or Bluetooth formats, with the processor (or a base station that relays the data to a remote processor) by wired connection, via the interne, by telephony, by cellular communications or any other suitable data transmission medium. The sensor can also include a memory that stores various reading and uploads data (or multiple data sets) to the processor in real time, at a later time or according to a predefined schedule.
In another aspect of the invention, methods of evaluating the progression of ALS in a patient are disclosed that can include the following steps of attaching at least a first accelerometer to a first body limb of a patient, detecting movement data, including the acceleration of the one or more limbs during a period of prescribed exercise, optionally storing the movement data in a memory associated with one or more of the accelerometers (or a base station in communication therewith), and outputting the movement data from the accelerometer or the memory to a processor for analyzing the movement data over time to evaluate the progression of ALS in the patient.
The methods can further include attaching a second accelerometer to a second body limb of the patient, attaching a third accelerometer to a third body limb of the patient or attaching accelerometers to all four limbs and outputting the data from the respective accelerometers to the processor to analyze each of the limb functions measured For example, the body limbs are selected from the group consisting of a left arm, a right arm, a left leg and a right leg, and in one preferred embodiment, four accelerometers are deployed on each of the wrists and ankles of the patient to obtain data from all four limbs.
In certain embodiments the methods can include analyzing the movement data by comparing acceleration vector magnitudes (VM) over time, the acceleration vector magnitudes being defined by the afore-described equation, wherein x, y, and z represent the magnitudes of limb acceleration as measured in the x, y and z directions. A decline in the average vector magnitude in one or more body limbs can indicate progression of ALS in the patient.
The methods of the present invention can further include the step of providing therapy or palliative care based on the measured score or analysis of patient function.
The present invention generally relates to devices, systems and methods for evaluating a neurological condition by employing a plurality of motion sensors. Each device, i.e., motion sensor, can be configured to be attached to a different body appendage. A memory can be associated with the plurality of sensors to periodically record movement data during periods of prescribed exercises. The devices and systems described herein can also include a processor for analyzing changes in movement data over time to evaluate the progression of the neurological condition. In one embodiment, the neurological condition is ALS and at least two motion sensors are employed such that one or both arms, one or both legs, or a combination thereof, of the patient has an associated sensor. The sensors can be accelerometers that measure the displacement, velocity and acceleration of an associated limb during periods of prescribed exercise. For example, changes in the patient's ability to repeat a series of limb-lifting exercises or the measurement of limb tremors associated with the conduct of the exercises can be correlated with norms and analyzed to classify the stage of ALS in a patient and/or predict the rate of progression.
The term “accelerometer” as used herein is intended to encompass instruments capable of measuring acceleration (changes in velocity) in at least one direction relative to an inertial frame. In certain embodiments, multiaxial accelerometer can used , for example, to measure changes in velocity relative to a three-dimensional Cartesian coordinate system (x, y and z directions). In some applications, two-axis or even one-axis measurements may suffice. Alternatively, acceleration can be measured based on non-Cartesian, e.g., cylindrical or spherical coordinates.
As used herein, the term “limb” or “appendage” refers to an arm and/or a leg. A body limb is selected from the group consisting of a left arm, a right arm, a left leg and a right leg. For example, an arm (left or right) consists of any region between a shoulder and a hand. This includes an arm, a forearm, and a wrist. A leg consists of any region between a hip and a foot. This includes an upper leg, a lower leg and an ankle.
In
The studies demonstrate that kinetic data, especially acceleration vector magnitude measures can be used to assess the stage and rate of progression of neurological diseases, especially in ALS.
The present application claims priority to provisional application no. 62/294,633, filed Feb. 12, 2016, titled “Measurement Of ALS Progression Based On Kinetic Data.” This application incorporates the content of the provisional application by reference in its entirety.
Number | Date | Country | |
---|---|---|---|
62294633 | Feb 2016 | US |